Noonan Kimberly, Borrello Ivan
Department of Oncology, Johns Hopkins University, 1650 Orleans St CRB-1, Rm 453, Baltimore, MD, 21231, USA.
Cancer Microenviron. 2011 Dec;4(3):313-23. doi: 10.1007/s12307-011-0086-3. Epub 2011 Aug 25.
The bone marrow (BM) is the site of disease in myeloma and possesses unique immune characteristics involved in the pathobiology of the disease. Interactions of plasma cells with stromal cells, osteoclasts, osteoblasts, myeloid and lymphoid cells make up the unique bone marrow milieu that mediates myeloma disease progression. Independently or through a complex network of interactions these cells impart immune changes leading to immune evasion and disease progression. The critical role of these factors in disease progression has led to the intense development of therapeutic strategies aimed at either disrupting the immune mechanisms mediating disease progression or augmenting those with anti-tumor benefits. This review discusses the major contributors of immunity in the bone marrow microenvironment, their interactions, and mechanisms whereby immune modulation can be translated into therapies with anti-myeloma efficacy.
骨髓（BM）是骨髓瘤的病变部位，具有参与该疾病病理生物学过程的独特免疫特征。浆细胞与基质细胞、破骨细胞、成骨细胞、髓系细胞和淋巴细胞之间的相互作用构成了介导骨髓瘤疾病进展的独特骨髓微环境。这些细胞独立地或通过复杂的相互作用网络引发免疫变化，导致免疫逃逸和疾病进展。这些因素在疾病进展中的关键作用促使人们大力开发治疗策略，旨在破坏介导疾病进展的免疫机制或增强具有抗肿瘤益处的免疫机制。本文综述讨论了骨髓微环境中免疫的主要贡献者、它们之间的相互作用，以及免疫调节可转化为具有抗骨髓瘤疗效的治疗方法的机制。
